Apolipoprotein C-III and the metabolic basis for hypertriglyceridemia and the dense low-density lipoprotein phenotype.
BACKGROUND
Here, we aim to identify defects of apolipoprotein (apo) B lipoprotein metabolism that characterize hypertriglyceridemia, focusing on apoC-III and apoE.


RESULTS
We studied the transport of plasma apoB within 21 distinct subfractions as separated by anti-apoC-III and anti-apoE immunoaffinity chromatography and ultracentrifugation in 9 patients with moderate hypertriglyceridemia and 12 normotriglyceridemic control subjects. Hypertriglyceridemia was characterized by a 3-fold higher liver secretion of very low-density lipoprotein (VLDL) that had apoC-III but not apoE and a 50% lower secretion of VLDL with both apoC-III and apoE (both P<0.05). This shift in VLDL secretion pattern from apoE to apoC-III resulted in significantly reduced clearance of light VLDL (-39%; P<0.05), compatible with the antagonizing effects of apoC-III on apoE-induced clearance of triglyceride-rich lipoproteins. In addition, rate constants for clearance were reduced for apoE-containing triglyceride-rich lipoproteins in hypertriglyceridemia, associated with increased apoC-III contents of these particles. LDL distribution shifted from light and medium LDL to dense LDL in hypertriglyceridemia through a quartet of kinetic perturbations: increased flux from apoC-III-containing triglyceride-rich lipoproteins, a shift in liver LDL secretion pattern from light to dense LDL, an increased conversion rate from light and medium LDL to dense LDL, and retarded catabolism of dense LDL.


CONCLUSIONS
These results support a central role for apoC-III in metabolic defects leading to hypertriglyceridemia. Triglyceride-rich lipoprotein metabolism shifts from an apoE-dominated system in normotriglyceridemic participants characterized by rapid clearance from circulation of VLDL to an apoC-III-dominated system in hypertriglyceridemic patients characterized by reduced clearance of triglyceride-rich lipoproteins and the formation of the dense LDL phenotype.
Zheng
Chunyu
C
Department of Nutrition, Harvard School of Public Health, Boston, MA 02115, USA.
Khoo
Christina
C
Furtado
Jeremy
J
Sacks
Frank M
FM
D000328:Adult; D053305:Apolipoprotein C-III / Q000378:metabolism*; D001055:Apolipoproteins B / Q000378:metabolism; D001057:Apolipoproteins E / Q000378:metabolism; D015243:Cholesterol, VLDL / Q000378:metabolism; D002846:Chromatography, Affinity; D004040:Dietary Carbohydrates / Q000008:administration & dosage; D004041:Dietary Fats / Q000008:administration & dosage; D005260:Female; D006801:Humans; D015228:Hypertriglyceridemia / Q000378:metabolism*; D007930:Leucine / Q000493:pharmacokinetics; D008077:Lipoproteins, LDL / Q000096:biosynthesis / Q000378:metabolism*; D008099:Liver / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D010641:Phenotype; D010649:Phenylalanine / Q000493:pharmacokinetics; D014280:Triglycerides / Q000378:metabolism
D053305:Apolipoprotein C-III; D001055:Apolipoproteins B; D001057:Apolipoproteins E; D015243:Cholesterol, VLDL; D004040:Dietary Carbohydrates; D004041:Dietary Fats; D008077:Lipoproteins, LDL; D014280:Triglycerides; D010649:Phenylalanine; D007930:Leucine